NASDAQ:CRSP
CRISPR Therapeutics AG
CRISPR Therapeutics AG's revenue fell 90.6% in fiscal 2025 to $3.5M while operating margin fell to −18933.6%. Free cash flow was −$345.9M, −9855.5% of revenue, and the diluted share count rose 6.6%.Summary generated from CRISPR Therapeutics AG's SEC filings. Latest annual report filed Feb 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$3.5M
Revenue growth−90.6%
Revenue, 5-yr CAGR+37.3%
Gross marginn/a
Operating margin−18933.6%
Net margin−16569.8%
ROICn/a
Return on equity−30.2%
Debt / equityn/a
Free cash flow−$345.9M
FCF margin−9855.5%
Share count change+6.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 915 | 1 | 371 | 37 | 4 |
| Operating income | 374 | −673 | −223 | −467 | −665 |
| Net income | 378 | −650 | −154 | −366 | −582 |
| Free cash flow | 457 | −533 | −270 | −145 | −346 |
Recent filings
- 4Insider transaction report
Oct 8, 2026 - 4Insider transaction report
Sep 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 3, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026 - 8-KDirector or officer change
Jun 4, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 4, 2026 - 8-KResults of operations and financial condition
May 4, 2026 - DEF 14AProxy statement
Apr 21, 2026